On August 6th, Jiangxi Tonglian Dongfeng Pharmaceutical Co., Ltd., an annual production capacity of 200 million tablets of a new drug, the production of a line of cansomycin tablets started in Leping Industrial Park in Jiangxi Province, and played a role in building the largest pharmaceutical chemical industry base in southern Yangtze River. Important role in promoting.
According to reports, the project has the characteristics of high technological content, low carbon environmental protection, etc., and can be fully connected with the Poyang Lake Ecological Economic Zone construction plan, and the product has a vast market. Colimycin was jointly developed by Shenyang Tonglian Group and the Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences using genetic recombination technology. It is the first new class of antibiotics with independent intellectual property rights in China. The project is planned to be completed in December of this year. After the project is completed and put into production, it is estimated that the annual output value will reach 3 billion yuan and the total annual profit will reach 600 million yuan.
The total investment of the Tonglian Dongfeng Company's new factory construction project is 440 million yuan. In addition to the production of the canomycin tablet production line, a new synthetic production line with an annual output of 3,000 tons of amoxicillin bulk drug will be newly built, with an annual output of 5 million amoxicillin capsules. Filling production line, with an annual output of 1,400 tons of penicillin powder injections.
According to reports, the project has the characteristics of high technological content, low carbon environmental protection, etc., and can be fully connected with the Poyang Lake Ecological Economic Zone construction plan, and the product has a vast market. Colimycin was jointly developed by Shenyang Tonglian Group and the Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences using genetic recombination technology. It is the first new class of antibiotics with independent intellectual property rights in China. The project is planned to be completed in December of this year. After the project is completed and put into production, it is estimated that the annual output value will reach 3 billion yuan and the total annual profit will reach 600 million yuan.
The total investment of the Tonglian Dongfeng Company's new factory construction project is 440 million yuan. In addition to the production of the canomycin tablet production line, a new synthetic production line with an annual output of 3,000 tons of amoxicillin bulk drug will be newly built, with an annual output of 5 million amoxicillin capsules. Filling production line, with an annual output of 1,400 tons of penicillin powder injections.